Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshitaka Nagai

Showing results (1-10 of 137) with videos related to

Pageof 14
Sort By:
Rinsho Shinkeigaku = Clinical Neurology|December 1, 2012
[Keywords for study of pathological conditions of neurodegenerative diseases]Yoshitaka Nagai
Rinsho Shinkeigaku = Clinical Neurology|December 25, 2009
[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases]Yoshitaka Nagai
Journal of Biochemistry|August 1, 2009
Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteinsHironobu Naiki, Yoshitaka Nagai
Neurochemistry International|May 7, 2022
Emerging roles of extracellular vesicles in polyglutamine diseases: Mutant protein transmission, therapeutic potential, and diagnosticsToshihide Takeuchi, Yoshitaka Nagai
Brain Sciences|October 12, 2017
Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine DiseasesToshihide Takeuchi, Yoshitaka Nagai
Rinsho Shinkeigaku = Clinical Neurology|January 27, 2012
[Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1]Yoshitaka Nagai, Nobuyuki Nukina
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 23, 2019
Molecular Mechanisms and Future Therapeutics for Spinocerebellar Ataxia Type 31 (SCA31)Kinya Ishikawa, Yoshitaka Nagai
Biochemical Society Transactions|December 23, 2021
The molecular pathogenesis of repeat expansion diseasesYuzo Fujino, Yoshitaka Nagai
Advances in Experimental Medicine and Biology|June 29, 2018
Repeat Expansion Disease ModelsMorio Ueyama, Yoshitaka Nagai
Frontiers in Neuroscience|March 1, 2021
Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesEiko N Minakawa, Yoshitaka Nagai
Pageof 14

Showing results (1-10 of 137) with videos related to

Sort By:
Pageof 14
Rinsho Shinkeigaku = Clinical Neurology|December 1, 2012
[Keywords for study of pathological conditions of neurodegenerative diseases]Yoshitaka Nagai
Rinsho Shinkeigaku = Clinical Neurology|December 25, 2009
[Molecular therapy targeting protein misfolding and aggregation for the polyglutamine diseases]Yoshitaka Nagai
Journal of Biochemistry|August 1, 2009
Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteinsHironobu Naiki, Yoshitaka Nagai
Neurochemistry International|May 7, 2022
Emerging roles of extracellular vesicles in polyglutamine diseases: Mutant protein transmission, therapeutic potential, and diagnosticsToshihide Takeuchi, Yoshitaka Nagai
Brain Sciences|October 12, 2017
Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine DiseasesToshihide Takeuchi, Yoshitaka Nagai
Rinsho Shinkeigaku = Clinical Neurology|January 27, 2012
[Selective degradation of expanded polyglutamine proteins by their specific recognition with QBP1]Yoshitaka Nagai, Nobuyuki Nukina
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|November 23, 2019
Molecular Mechanisms and Future Therapeutics for Spinocerebellar Ataxia Type 31 (SCA31)Kinya Ishikawa, Yoshitaka Nagai
Biochemical Society Transactions|December 23, 2021
The molecular pathogenesis of repeat expansion diseasesYuzo Fujino, Yoshitaka Nagai
Advances in Experimental Medicine and Biology|June 29, 2018
Repeat Expansion Disease ModelsMorio Ueyama, Yoshitaka Nagai
Frontiers in Neuroscience|March 1, 2021
Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine DiseasesEiko N Minakawa, Yoshitaka Nagai
Pageof 14